SCHEMBL4909020

SCHEMBL4909020

CS(=O)(=O)Nc1cccc(Nc2nc(NC3CCCC3)c3nc[nH]c3n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 9/20 0.48
ADORA1 P30542 7/20 0.48
ADORA2A P29274 6/20 0.48
PTK2 Q05397 2/20 0.47
PIK3CD O00329 1/20 0.45
PIK3CA P42336 1/20 0.45
PIK3CB P42338 1/20 0.45
PIK3CG P48736 1/20 0.45
JAK2 O60674 2/20 0.43
BRD4 O60885 2/20 0.43
USP2 O75604 3/20 0.43
CYP1A2 P05177 3/20 0.43
CLK4 Q9HAZ1 3/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C19 P33261 2/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.42
FYN P06241 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916898 0.98 ADORA3 (0.45) ADORA3ADORA1ADORA2APTK2PIK3CD
SCHEMBL4917250 0.90 ADORA3 (0.49) ADORA3ADORA1ADORA2APIK3CDPIK3CA
SCHEMBL4919823 0.88 ADORA3 (0.46) ADORA3ADORA1ADORA2AJAK2BRD4
SCHEMBL4937118 0.86 JAK2 (0.41) PTK2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4916405 0.86 JAK2 (0.41) PTK2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4917380 0.86 PIK3CD (0.38) ADORA3ADORA1ADORA2APTK2PIK3CD
SCHEMBL4937142 0.86 JAK2 (0.41) PTK2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL4914661 0.84 PTK2 (0.43) PTK2JAK2BRD4
SCHEMBL4920899 0.83 ADORA3 (0.53) ADORA3ADORA1ADORA2APIK3CDPIK3CA
SCHEMBL4915716 0.83 BRD4 (0.41) PTK2PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK ADORA3 662/4885ADORA1 1305/4885ADORA2A 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.